A Multi-Center, Open Label, Randomized Phase 2 Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma
Phase of Trial: Phase II
Latest Information Update: 08 Dec 2017
At a glance
- Drugs AGS 16C3F (Primary) ; Axitinib
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Sponsors Agensys
- 30 Oct 2017 Planned End Date changed from 30 Jun 2018 to 1 Jan 2019.
- 30 Oct 2017 Planned primary completion date changed from 31 Jan 2018 to 1 Jan 2019.
- 13 May 2016 Status changed from not yet recruiting to recruiting.